Trial Profile
A Multi-Center, Double-Blind, Placebo-Controlled Randomized, Efficacy and Safety Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Denufosol (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Acronyms TIGER-1
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 10 Apr 2012 New trial record
- 01 Mar 2012 Primary endpoint 'Forced expiratory volume in 1 second at 24 weeks' has been met, according to results of the economic analysis published in Value in Health.
- 01 Mar 2012 Results of the economic analysis published in Value in Health.